Laurie(Myers)LeeMD

Allergy & Immunology • King Of Prussia, PA

VP, R&D, Transplant Therapy Area at CSL Behring

Join to view full profile

Dr. Lee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lee's full profile

Already have an account?

Office
1020 First Avenue
King Of Prussia, PA 19406
Phone+1 215-221-9125

Education & Training

Duke University HospitalFellowship, Allergy and Immunology, 1995 - 1997
Nationwide Children's Hospital/Ohio State UniversityResidency, Pediatrics, 1992 - 1995
Ohio State University College of MedicineClass of 1992

Certifications & Licensure

NC State Medical License 1995 - 2025
American Board of Allergy and Immunology Allergy & Immunology
American Board of Pediatrics Pediatrics

Clinical Trials

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients Start of enrollment: 2019 Oct 14
Terminated
Phase 3
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Start of enrollment: 2018 Feb 27
Active, not recruiting
Phase 1, Phase 2
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant Start of enrollment: 2018 Feb 21
Completed
Phase 1, Phase 2
A Pilot Trial of Clazakizumab in Late ABMR Start of enrollment: 2018 Jan 16
Completed
Phase 2
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant Start of enrollment: 2019 Mar 27
Recruiting
Phase 2, Phase 3
Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705) Start of enrollment: 2020 Jan 09
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III O...
Soichiro Hozawa, Hiroyuki Ohbayashi, Michiko Tsuchiya, Yu Hara, Laurie A Lee
Journal of Asthma and Allergy. 2021-07-06
No dose effect observed with chronic fluticasone propionate on growth velocity in children.
Laurie A Lee, Søren Pedersen, Steven Pascoe, Stanley J. Szefler, Warren Lenney
Pediatric Allergy and Immunology. 2021-02-01
106 citations
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, ra...
Laurie A Lee, Zelie Bailes, Neil Barnes, Louis-Philippe Boulet, Dawn Edwards
The Lancet. Respiratory Medicine. 2021-01-01

Journal Articles

Article Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma via Intercellular Transfer of Splicing Factors
Ahmed Mohyeldin, Ichiro Nakano, L James Lee, ScienceDirect

Authored Content

On-Chip Clonal Analysis of Glioma-Stem-Cell Motility and Therapy ResistanceJuly 2016